SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001819790-24-000024
Filing Date
2024-03-05
Accepted
2024-03-05 16:09:18
Documents
14
Period of Report
2024-03-05
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K tars-20240305.htm   iXBRL 8-K 24751
  Complete submission text file 0001819790-24-000024.txt   151650

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20240305.xsd EX-101.SCH 1892
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20240305_lab.xml EX-101.LAB 22530
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20240305_pre.xml EX-101.PRE 13037
15 EXTRACTED XBRL INSTANCE DOCUMENT tars-20240305_htm.xml XML 2929
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 24720392
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)